We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its lead drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquapl... Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its lead drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex. Show more
Strategic merger with Rafael Holdings to combine two companies and advance TrappsolĀ® Cycloā¢ for NPC1 patients expected to close Q4 2024 Company on track for topline data from the 48-week interim...
NEWARK, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the fourth quarter and the full fiscal year ended July 31, 2024...
TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the...
Two posters presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024 Pivotal TransportNPCā¢ study is the most comprehensive ongoing controlled pivotal...
Kuehn Law Encourages CYTH, ARCH, CEIX, and VGR Investors to Contact Law Firm PR Newswire NEW YORK, Aug. 26, 2024 NEW YORK, Aug. 26, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation...
Cyclo Therapeuticsā TransportNPCā¢ Phase 3 clinical trial for TrappsolĀ® Cycloā¢ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0138 | -2.03539823009 | 0.678 | 0.72 | 0.6 | 29214 | 0.67989617 | CS |
4 | -0.0478 | -6.71348314607 | 0.712 | 0.77 | 0.6 | 22860 | 0.69643472 | CS |
12 | -0.0258 | -3.73913043478 | 0.69 | 0.82 | 0.5946 | 30782 | 0.71246345 | CS |
26 | -0.6158 | -48.109375 | 1.28 | 1.4 | 0.5946 | 51661 | 0.97665031 | CS |
52 | -0.8458 | -56.0132450331 | 1.51 | 2.115 | 0.5946 | 72444 | 1.3620454 | CS |
156 | -4.3158 | -86.6626506024 | 4.98 | 5.2499 | 0.5946 | 73128 | 1.80365627 | CS |
260 | -3.6858 | -84.7310344828 | 4.35 | 17.75 | 0.5946 | 200971 | 6.18950343 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions